World Media

Korean firm to make Russia’s Covid-19 vaccine amid lingering doubt

S. Korean bio firm GL Rapha to produce Russian COVID-19 vaccine

"We are sharing results with India's drug regulator".

RB Kamal, principal of Ganesh Shankar Vidyarthi Medical College, confirmed the clinical trials will start from next week. For this, more than 180 volunteers have registered themselves. Head of the research Saurabh Agarwal will determine the dosage of the vaccine to be administered. After a single dose, volunteers will be monitored periodically with monitoring and then decide if a further dose is given.

But RDIF said that requests had already come in for than 1.2 billion doses of the Sputnik V vaccine from over 50 countries, which it added would be supplied through global partners in South Korea, India, Brazil, China, and other countries. He said the effect of the vaccine on the volunteers will be studied for seven months after the same is administered once, twice or thrice within an interval of 21 days. He told that after observing the effect of the vaccine for one month, the officials will be forwarded from its result and a decision will be taken accordingly.

The Ethics Committee of the college has also given permission for the trails, he said.

The Russian Direct Investment Fund (RDIF) said that GL Rapha, a Korean biotech firm, will manufacture 150 million doses of Sputnik V, a Russian-developed Covid-19 vaccine, annually. Over 20,000 participants have been vaccinated with the first dose of the Sputnik V vaccine and more than 16,000 have received both the first and second doses of the vaccine.

Pointing to the need for worldwide cooperation, Kirill Dmitriev, RDIF-CEO said, "Sputnik V is based on safe and effective platform of human adenoviral vectors".

Science, Technology and Innovation Minister Khairy Jamaluddin said communications with eight of the producers was made directly, while the other two was through the Covid-19 Vaccine Global Access Facility (COVAX).

"The parties intend to commence production in December 2020 and a rollout of the Sputnik V vaccine in January 2021", the RDIF said in a press release posted on a website.